Print

Preferences Survey for Women With an Inherited BRCA Mutation and Without a Cancer Diagnosis

https://www.facingourrisk.org/research-clinical-trials/study/239/preferences-survey-for-women-with-an-inherited-brca-mutation-and-without-a-cancer-diagnosis


Online survey for women with a BRCA1 or BRCA2 inherited mutation and no personal history of cancer.

Study Contact Information:

If you have any questions, feel free to contact the study investigator, Dr. Laura Havrilesky at [email protected] or the study coordinator, Amelia Scott at [email protected].


About the Study

This study is no longer enrolling people. 

We hope to understand women’s preferences about the benefits and effects of cancer-preventing surgeries. In this survey of women ages 25-50 with an inherited BRCA1 or BRCA2 mutation and no personal history of cancer, we present scenarios and ask participants to make hypothetical choices. Your responses will help us to design educational tools for people who are at high risk of breast and ovarian cancer who face personal decisions about cancer prevention.

What the Study Involves

This is a web-based survey that should take about 25 minutes to complete.

It includes questions about you such as prior medical and surgical history related to your cancer risk, as well as your opinions about different management options that are available to women who are at high risk of breast and ovarian cancer. There is no direct medical benefit to you from participating in this study.

The survey will not collect any personal information that could be used to identify you. You may complete the survey at your convenience. Click here to take the survey.

Lead Researcher

Laura Havrilesky MD, Duke Cancer Institute, Durham, NC


This Study is Open To:

This study is no longer enrolling people. 

This Study is Not Open To:

This study is no longer enrolling people. 


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.